Investors' Soapbox AM

Gilead a Given for Hepatitis C Favorite

AbbVie is underappreciated on the Street while Merck has made strides.

February 11, 2014

Credit Suisse

Given intense debate on the competitiveness of the all-oral hepatitis C treatment regimens that Gilead Sciences and AbbVie will launch later this year, we conducted a survey with 40 specialists to better assess the market potential for each company.

While Gilead (ticker: GILD) is poised to be the clear market-share leader...